Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 30/100

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

Key Takeaway: ADMA Biologics, Inc. is under legal scrutiny due to a securities class action lawsuit filed in the United States District Court for New Jersey. The lawsuit alleges that ADMA and its executives failed to disclose material information and engaged in potentially misleading practices during the class period from August 9, 2024, to March 25, 2026. A lead plaintiff deadline has been set for August 10, 2026, for investors who suffered losses exceeding $100,000. Investors are encouraged to submit claims and review their legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA is facing a securities class action lawsuit for alleged material misstatements.
  • Claims of undisclosed related party transactions and misleading revenue reporting.
  • The lawsuit suggests that executives failed to maintain adequate internal controls.

Full Press Release Details

NEW ORLEANS, June 18, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against ADMA Biologics, Inc. (NasdaqGM: ADMA) (“ADMA” or the “Company”), if they purchased or otherwise acquired the Company’s securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
ADMA investors should visit us at https://claimsfiler.com/cases/nasdaq-adma-1/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
ADMA and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company engaged in an undisclosed related party transaction; (ii) the Company used channel stuffing to create an appearance of revenue; (iii) the Company lacked adequate internal controls; and (iv) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
The case is Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-04793.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file lead plaintiff applications against ADMA?

Investors must file lead plaintiff applications by August 10, 2026.

What is the Class Period for the ADMA Biologics lawsuit?

The Class Period runs from August 9, 2024, to March 25, 2026.

Where can I find more information about the ADMA lawsuit?

Visit https://claimsfiler.com/cases/nasdaq-adma-1/ for more details.

Who can assist with legal options regarding the ADMA case?

Lawyers at Kahn Swick & Foti, LLC can provide assistance.

What is ClaimsFiler's mission?

ClaimsFiler aims to help investors recover from securities class action settlements.

Last updated: Jun 18, 2026